Trial Profile
Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
Status:
Not yet recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Andecaliximab (Primary) ; Bevacizumab (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms MARELLE01
- 23 Aug 2018 New trial record